Controlled human infection models to accelerate vaccine development

RKM Choy, AL Bourgeois… - Clinical Microbiology …, 2022 - Am Soc Microbiol
The timelines for developing vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …

Coping strategies for pertussis resurgence

X Nian, H Liu, M Cai, K Duan, X Yang - Vaccines, 2023 - mdpi.com
Pertussis (whooping cough) is a respiratory disease caused primarily by Bordetella
pertussis, a Gram-negative bacteria. Pertussis is a relatively contagious infectious disease in …

Novel approaches to reactivate pertussis immunity

G Blanchard-Rohner - Expert Review of Vaccines, 2022 - Taylor & Francis
Introduction Whole cell and acellular pertussis vaccines have been very effective in
decreasing the deaths of neonates and infants from Bordetella pertussis. Despite high …

Evaluation of anti-PT antibody response after pertussis vaccination and infection: the importance of both quantity and quality

AM Barkoff, A Knuutila, J Mertsola, Q He - Toxins, 2021 - mdpi.com
Pertussis toxin (PT) is considered the main virulence factor causing whooping cough or
pertussis. The protein is widely studied and its composition was revealed and sequenced …

[HTML][HTML] Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant …

K Chokephaibulkit, T Puthanakit… - Vaccine, 2024 - Elsevier
Introduction Recombinant acellular pertussis (ap) vaccines containing genetically
inactivated pertussis toxin (PT gen) and filamentous hemagglutinin (FHA) with or without …

Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines

P Pitisuttithum, J Dhitavat, C Sirivichayakul… - …, 2021 - thelancet.com
Background Recombinant pertussis vaccines inducing long-lasting immune responses
could help to control the rise in pertussis. We here report on persisting antibody responses 2 …

Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a …

P Pitisuttithum, K Chokephaibulkit… - The Lancet Infectious …, 2018 - thelancet.com
Background The immunogenicity of acellular pertussis vaccines and persistence of immunity
after vaccination might be improved by using genetically inactivated pertussis toxin (PTgen) …

New pertussis vaccines: a need and a challenge

D Hozbor - Pertussis Infection and Vaccines: Advances in …, 2019 - Springer
Effective diphtheria, tetanus toxoids, whole-cell pertussis (wP) vaccines were used for
massive immunization in the 1950s. The broad use of these vaccines significantly reduced …

A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2 …

S Sricharoenchai, C Sirivichayakul… - The Lancet Infectious …, 2018 - thelancet.com
Background Increasing evidence shows that protection induced by acellular pertussis
vaccines is short-lived, requiring repeated booster vaccination to control pertussis disease …

Assays for determining pertussis toxin activity in acellular pertussis vaccines

K Markey, C Asokanathan, I Feavers - Toxins, 2019 - mdpi.com
Whooping cough is caused by the bacterium Bordetella pertussis. There are currently two
types of vaccines that can prevent the disease; whole cell vaccines (WCV) and acellular …